⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 23, 2026HaematologicaOpen Access

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing

Niveditha Ravindra Rasha W Al-Ali Justin Lack Clifton L. Dalgard Eddy vanCollenburg Adam Corner Lan Beppu Harry Erba Megan Othus R. Coleman Lindsley Jerald P. Radich Laura W. Dillon Christopher S. Hourigan

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to develop personalized assays for measuring residual disease in acute myeloid leukemia using whole-genome sequencing.
Utilized whole-genome sequencing to identify biomarkers for measurable residual disease in patients with acute myeloid leukemia.
Developed personalized assays based on identified genetic targets to monitor disease progression.
Demonstrated the ability to tailor disease monitoring based on individual genomic profiles, enhancing detection sensitivity.
Results indicate potential improvements in treatment decisions based on measurable residual disease status.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Demonstrates improved detection of residual disease in acute myeloid leukemia, suggesting enhanced treatment guidance.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ravindra et al. (2026) studied this question.

synapsesocial.com/papers/6a65a3e4d3aea3239cd76d80 https://doi.org/10.3324/haematol.2026.300715

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Abstract 1067: Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistanceOriginal Research · 2026
2Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid LeukemiaOriginal Research · 2026
3Abstract 5307: Analytical performance of an ultrasensitive whole genome sequencing assay for molecular residual disease detection.Original Research · 2026
4Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencingOriginal Research · 2019 · 24 citations
5Abstract 5300: Clinical utility of whole genome sequencing for upfront risk stratification in AML and MDS patientsReview · 2026

Toward a harmonized assessment of MRD by NGS: blinded pilot study of NGS assays by MPAACT consortium2026
Whole genome sequencing in acute myeloid leukemia2026
Patient‐specific genomic measurable residual disease markers for monitoring acute myeloid leukaemia and myeloid malignancy2026
The importance of preparation for or achieving accreditation for small and high volume hematopoietic cell transplantation programsHaematologica · 2026
BCL6 in B-cell lymphomas: old target, new tricks?Haematologica · 2026

More from Haematologica

More from Harvard University

More from National Institutes of Health

More from Duke University

More from Dana-Farber Cancer Institute

More from Fred Hutch Cancer Center

More from National Heart Lung and Blood Institute

More from Uniformed Services University of the Health Sciences

More from National Institutes of Health Clinical Center

More from Breast Cancer Research Foundation

More from Institute of Cancer Research

More from Bio-Rad (United States)